Recent Finacing
Recent Raise
Surrozen designs tissue-specific antibody therapeutics that modulate Wnt signaling using proprietary SWEETS (R-spondin‑mimetics) and SWAP (Wnt‑mimetics) platforms, advancing liver and intestinal IND candidates.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Surrozen.
